title: Current status of radioligand antibodies in the treatment of malignancy.
abstract: Monoclonal anti-tumor antibodies labeled with a radioactive moiety present an exciting new approach to cancer therapy. With the advent of hybridoma technology, monoclonal antibodies can now be produced in quantity. Indeed, antibodies against tumor-related and tumor-specific antigens have been produced, labeled with a radioactive substance, and used therapeutically. The rationale for this therapeutic approach and the results of human clinical trials will be reported herein.
authors.affiliation: Division of Radiation Therapy, University of Arkansas for Medical Sciences, Little Rock 72205.
authors.forename: A W
authors.initials: AW
authors.lastname: Maners
authors.forename: M M
authors.initials: MM
authors.lastname: Sanders
authors.forename: A A
authors.initials: AA
authors.lastname: Pappas
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology; D000912:Antibodies, Neoplasm; D000918:Antibody Specificity; D006801:Humans; D006825:Hybridomas; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D009369:Neoplasms / Q000532:radiotherapy*
chemical_list: D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D007457:Iodine Radioisotopes